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1. Introduction 
Pregnancy in women with pulmonary arterial hypertension (PAH) due to defined or 
unknown causes is associated with greatly increased maternal morbidity. Significant 
respiratory, cardiac, and hematologic adaptations occur during pregnancy that may 
exacerbate the hemodynamic consequences of PAH and may precipitate malignant 
dysrhythmias and acute right ventricular overload and failure. Because of these potentially 
fatal consequences, the European Society of Cardiology and the American College of 
Cardiology/American Heart Association dissuade conception in women with PAH and 
recommend termination should pregnancy occur (Oakley 2003). Recent reviews suggest that 
significant progress has been achieved in the treatment and management of PAH during 
pregnancy (Bedard 2009). From 1978 to 1996 the overall maternal mortality rate was 38% 
and declined to 25% from 1997 to 2007 (Bedard 2009). Despite this improvement, mortality 
rates remain significantly elevated and the consideration of pregnancy in women with PAH 
should be thoroughly reviewed and discussed prior to conception (Roberts 1990) and, for 
those women with PAH who become pregnant or are diagnosed with PAH during 
pregnancy, a multidisciplinary management team with expertise in high risk pregnancy, 
maternal-fetal medicine, and pulmonary hypertension is warranted (Kiely 2010). 
In this chapter, we will review the maternal physiological changes that occur during 
pregnancy and their effects on pulmonary vascular and cardiac function, physical 
examination findings and diagnostic studies of PAH during pregnancy, the epidemiology 
and outcomes of pregnancy in women with PAH, and current pharmacologic and 
management strategies for the treatment of these patients. 
2. Physiologic changes during pregnancy (Table 1) 
2.1 Respiratory  
Profound changes in respiratory physiology occur during pregnancy. Basal oxygen 
consumption increases by 50 ml/min by term (Thornberg 2000). This increased oxygen 
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demand is met by augmentation of minute ventilation. Alveolar ventilation increases due to 
progesterone, effects of reduced osmolality, increased angiotensin II and vasopressin 
(Thornberg 2000). The elevation in alveolar ventilation is caused primarily by a 25-40% 
increase in tidal volume (Fujitani 2005) and produces a fall in alveolar PCO2 from 38 torr to 30 
torr at term (Thornberg 2000). The total lung capacity may decline slightly but does not change 
significantly during pregnancy. In contrast, functional residual capacity declines by 20-30% 
due to elevation of the diaphragm by the gravid uterus, reduced downward pull by the 
abdomen, and alterations in the chest wall that diminish outward recoil (Hegewald 2011). 
 
(adapted from Hegewald 2011, Hameed 2007) 
Table 1. Physiologic Changes during Pregnancy 
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2.2 Pulmonary vasculature 
Blood volume expands up to 40% by term (Thornberg 2000) and most of the increase is due 
to plasma volume increases (Madden 2009). In addition, the red cell mass enlarges by 30% 
(Thornberg 2000). Cardiac output (CO) increases by more than 50% by mid-third trimester 
due to augmentation of stroke volume, quickened heart rate, reduced afterload, and 
increased left ventricular (LV) outflow area (Thornberg 2000, Capeless 1989, Duvekot 1994, 
Mashini 1987, Vered 1991). Heart rate accelerates gradually throughout gestation whereas 
engorgement of stroke volume (SV) stabilizes by 20 weeks (Atkins 1981). SV increases due to 
cardiac remodeling with enlargement of all four chambers, elevation in end diastolic 
volume, and maintenance of ejection fraction (Thornberg 2000, Fujitani 2005). Cross 
sectional echocardiographic studies of left ventricular mass and function demonstrate a 
greater than 50% increase in LV mass during pregnancy; LV diastolic function also increases 
during the first two trimesters but then declines during the last trimester (Kametas 2001). 
Despite the elevated CO, systolic and diastolic arterial blood pressure decline and pulse 
pressure widens slightly during pregnancy. With the increase in CO and decrease in blood 
pressure, peripheral vascular resistance declines over the first trimester and remains low for 
the remainder of pregnancy without further reduction. Aortic diameter and compliance, 
venous capacitance, and blood volume all increase (Thornberg 2000). 
Although pulmonary blood flow increases dramatically during pregnancy, a reduction in 
pulmonary vascular resistance (PVR) maintains pulmonary arterial pressure (PAP) constant 
throughout pregnancy. Serial pulsed Doppler echocardiographic studies of 13 women 
during pregnancy demonstrated the mean PAP before pregnancy was 13.8 mm Hg and did 
not change throughout pregnancy; however, pulmonary blood flow increased from 4.88 to 
7.19 L/min during pregnancy with a decline in pulmonary vascular resistance from 2.85 to 
2.17 resistance units. PVR returned to normal by 6 months post partum. (Robson 1991) 
CO may increase by 25-30% during the second stage of labor due to uterine contractions and 
by up to 80% immediately post partum due to autotransfusion of blood from the uterus to 
the systemic circulation (Madden 2009). Postpartum, heart rate, systemic vascular resistance, 
and cardiac output decrease and cardiac enlargement begins to regress. Blood volume 
normalizes quickly and hemodynamic parameters including cardiac output, stroke volume, 
ventricular volume, myocardial contractility, and pulmonary and systemic vascular 
resistance return to pre-pregnancy levels over several weeks whereas cardiac remodeling 
occurs over several months (Weiss 2000, Capeless 1991, Duvekot 1994). 
2.3 Hematologic  
There is a significant increase in procoagulant activity during pregnancy due to increases in 
clotting factor concentrations and decreases in quantity and activity of physiological 
anticoagulants (Brenner 2004). The levels of factors II, V, VII, VIII, IX, X, XII, fibrinogen and 
von Willebrand factor increase whereas protein S activity declines and resistance to 
activated protein C develops (Brenner 2004, Montavon 2008). There are also increases in 
circulating prothrombin fragments (PF1+2) and thrombin-antithrombin complexes. 
Microparticles shed from the cell membranes of maternal endothelial cells and platelets are 
also associated with enhanced thrombosis. Throughout pregnancy, the risk of venous 
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thrombosis is increased 4-10 fold and is 3-4 fold higher post partum compared with 
pregnancy (Brenner 2004, Montavon 2008). The platelet count generally decreases during 
pregnancy because of hemodilution and increased destruction (Thornton 2010). In women 
with pre-existing PAH, these hematologic changes may predispose to in situ thrombosis 
within the already deranged pulmonary vasculature exacerbating elevations in pulmonary 
vascular resistance and precipitating right ventricular strain and potentially failure. 
3. History and physical examination 
3.1 History 
Cardiopulmonary symptoms are common throughout pregnancy. Progressive fatigue, 
weariness, and breathlessness frequently occur during pregnancy. Palpitations related to 
tachycardia are often experienced. Other common symptoms of pregnancy include pedal 
edema, fatigue, and reduced exercise tolerance (Hameed 2007). Supine hypotension may 
occur in up to 10% of pregnant women and may cause lightheadedness, dizziness, and 
occasionally syncope (Hameed 2007). The symptoms of PAH are very similar and may 
include exertional breathlessness or syncope, fatigue, dizziness, lower extremity edema, 
palpitations, chest discomfort, and tachycardia. The strong similarity between the clinical 
manifestations of normal pregnancy and the symptoms of PAH confound the recognition 
and diagnosis of PAH during pregnancy.  
A careful clinical history helps to identify or exclude recognized causes of PAH. A thorough 
medication history including prior use of anorexigens or chemotherapeutic agents should be 
elicited (Rubin 2005). Serologies can establish prior exposures to HIV and hepatitis B and C. 
A history of prior or familial thrombosis should prompt consideration of chronic thrombo-
embolic disease. Other pulmonary processes such as concurrent interstitial lung disease 
should be pursued with imaging studies such as high resolution chest computed 
tomography and pulmonary function testing. A thorough history of skin, joint, and muscle 
symptoms as well as serologic testing can determine the presence of a concurrent connective 
tissue disorder. A careful history and evaluation for congenital and acquired cardiac 
disorders should be considered because many women with PAH during pregnancy have 
known or undiagnosed cardiac disease.  
3.2 Physical examination 
Cardiac auscultatory changes are present in over 90% of pregnant women and are usually 
physiologic flow murmurs caused by cardiac dilation, increased blood volume, and elevated 
cardiac output. Tricuspid or pulmonic regurgitation occurs in over 90% of pregnant women 
and 28% have echocardiographic evidence of mitral regurgitation (Hameed 2007). 
Pregnancy-associated flow murmurs frequently occur during mid-systole and are present at 
the left lower sternal border and pulmonic areas (Hurst 1958, O’Rourke 1970). In women 
with PAH, signs of right ventricle enlargement or overload may include the presence of a 
right ventricular lift, prominent P2, right sided S4 gallop, and the murmur of tricuspid 
regurgitation. Tricuspid valve insufficiency may be manifest by elevated jugular venous 
pressure, hepatojugular reflux, and a pulsatile liver. Thus, the cardiac findings of normal 
pregnancy and PAH are very similar and the lack of distinguishing clinical features may 
delay further studies to diagnose the presence of elevated pulmonary pressures. 
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PAH may cause right ventricular hypertrophy or strain which can be detected by 
electrocardiographic changes. The electrocardiographic manifestations of cor pulmonale are 
relatively specific, 86%, but not sensitive, 51%, for PAH and do not correlate with the 
severity of PAH (Oswald-Mammosser 1987; Himelman 1988). Electrocardiographic features 
that suggest PAH include: A) P pulmonale, P-wave amplitude > 2.5 mm in leads II, III, 
and/or aVF; B) S1, S2, S3 pattern; C) an S1 Q3 pattern; D) incomplete or complete right bundle 
branch block; E) evidence of RVH: R axis deviation ≥ 100°, dominant R wave in lead V1 ≥ 7 
mm in amplitude, ST segment depression and T wave inversion in leads V1 to V4, and deep 
S waves in leads V5, V6, I and aVL with a QRS duration < 0.12 s; and F) low voltage QRS 
(Barbera et al 2003; Harrigan and Jones 2002). Pregnancy is associated with 
electrocardiographic changes that may obfuscate the electrocardiographic recognition of 
PAH: A) left axis deviation; B) reduced QRS voltage; C) T-wave inversion in lead III; D) Q-
waves and inverted P-waves in lead III that may normalize with inspiration; E) sinus 
tachycardia; F) presence of premature atrial and ventricular beats; and G) other 
dysrhythmias (Hameed 2007). Thus, pregnancy-associated changes in the electrocardiogram 
may obscure the electrocardiographic manifestations of PAH, delaying or thwarting its 
recognition and diagnosis. 
4. Effects of normal pregnancy related vascular changes on pre-existing PAH 
PAH is associated with increased PAP due to elevated PVR caused by vascular remodeling 
and local thrombus formation that can produce cor pulmonale and RV failure. Individuals 
with pre-existing PAH have difficulty tolerating the physiologic changes of pregnancy 
especially the elevation of heart rate and circulating blood volume. CO may have been 
reduced by increased PVR and the right ventricle may not be able to increase output due to 
the elevated afterload. The subsequent decrease in left ventricular preload may further 
accentuate the decline in systemic blood pressure due to an inability to compensate for the 
reduction in SVR that occurs during pregnancy. The fixed pulmonary vasculature of PAH 
may preclude or attenuate the physiologic decline in PVR that occurs during pregnancy to 
accommodate the increase in pulmonary blood volume and flow. Any augmentation of PVR 
(due to in situ or metastatic pulmonary vascular thrombosis, hypoxemia, acidosis, or 
hypercarbia) increases RV work and may trigger pulmonary hypertensive crisis, RV failure, 
acute reduction in LV preload, and precipitous reduction in systemic blood pressure 
(Warnes 2004, Madden 2009). 
Pregnancy-related physiologic changes in coagulation may accentuate in situ thrombosis 
within the pulmonary vasculature or pulmonary emboli that may further impede 
pulmonary blood flow and precipitate a critical reduction in RV function and systemic 
hypotension (Madden 2009). 
Diagnosis of unrecognized PAH during pregnancy may be difficult as many of the cardiac 
changes of pregnancy may mask or mimic the findings of PAH. The presence of PAH may 
be manifest by signs and symptoms of right heart failure, PAH crisis with acute RV failure, 
dysrhythmias, and pulmonary thromboembolic disease. Exertional breathlessness out of 
proportion to that expected during pregnancy may be the sole symptom of PAH. The 
differential diagnosis includes pre-existing cardiac abnormalities, patent foramen ovale, 
asthma, peripartum cardiomyopathy, and thromboembolic disease. 
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5. Screening for PAH before or during pregnancy 
A retrospective review of 27 patients undergoing echocardiography and right heart 
catheterization (RHC) during pregnancy from 1990 to 2000 showed that echocardiography 
significantly over-estimated the presence and severity of PAH (Penning 2001). Over three 
quarters of these patients had structural heart defects and most were due to congenital 
cardiac disease. Nearly one third of patients with PAH estimated by echocardiography had 
normal pressures at the time of RHC. This overestimation of the presence of PAH by 
echocardiography may be due to the methodology used to calculate PAP: the gradient 
between the right atrium and right ventricle was determined using the modified Bernoulli 
equation, 4 v2, and the right atrial pressure was estimated from the degree of collapse of the 
inferior vena cava (IVC) during inspiration (Hemnes 2009). However, the increase in blood 
volume during pregnancy may reduce respiratory variation in IVC diameter and lead to 
overestimation of right atrial (RA) pressure causing the calculated PAP to be falsely 
elevated. The average sPAP (systolic PAP) determined echocardiographically was 59.6 mm 
Hg but was only 54.8 when measured hemodynamically (p<0.005). In another study of 18 
patients undergoing RHC and echocardiography, one third of patients diagnosed with PAH 
by echocardiography had normal pressures on RHC. Although the echocardiographically 
estimated sPAP was 66.3 mm Hg and the average sPAP measured at RHC was 62.7 mm Hg, 
the two measurements correlated significantly. These studies show that Doppler 
echocardiography is not specific for the determination of PAH and up to one third of 
individuals with elevated PAP’s by echocardiography may have normal pulmonary 
pressures measured by RHC. Thus, invasive hemodynamic measurement is essential for the 
diagnosis and subsequent management of PAH during pregnancy. 
6. Preconception counseling 
6.1 Clinical outcomes: Morbidity and mortality-maternal and fetus 
In a systemic review of 73 pregnant women with PAH from 1997 to 2007, 29 (40%) had 
idiopathic PAH, 29 (40%) had PAH associated with congenital heart disease, and 15 (21%) had 
other causes of PAH (Bedard 2009). The diagnosis of idiopathic PAH was known prior to 
pregnancy in only 45% of the women, whereas over 75% of women with other causes of PAH 
were known to have PAH prior to conception. Of those with idiopathic PAH, the mortality 
rate was 17%, 2 died during pregnancy and 3 died post partum. The causes of death included 
refractory right heart failure, circulatory collapse, and PAH crisis. Of those with PAH 
associated with congenital heart disease, 8 (28%) died during the post partum period due to 
right heart failure, pulmonary thromboembolism (PTE), cardiac arrest, PAH crisis, and 
bacterial endocarditis. Five patients (33%) with other causes of PAH died, 1 during pregnancy 
and 4 post partum. Right heart failure and PTE were the major causes of death. Neonatal or 
fetal death occurred in 9.6% and premature delivery occurred in nearly all pregnancies. 
7. Management of pulmonary hypertension during pregnancy 
7.1 General medical management  
Currently, there are no clear consensus guidelines for the management of PAH in 
pregnancy; however, several case series have been published in the last two decades that 
provide guidance for the evaluation, treatment, and monitoring of this high risk patient 
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group. If PAH is suspected, a thorough evaluation should ensue. RHC is required for 
definitive confirmation of the diagnosis of PAH as well as the assessment of disease severity 
(McLaughlin 2009). A multidisciplinary team approach to the care of PAH in pregnancy has 
been utilized successfully (Garabedian 2010). This approach is associated with improved 
survival compared with historical data (Kiely 2010, Smedstad 1994). The multidisciplinary 
team includes physicians and staff with expertise in pulmonary vascular disease, 
hematology, maternal-fetal medicine, high risk obstetrics, and obstetric anesthesia.  
The pharmacotherapeutic management of PAH requires a multifaceted approach with the 
goal of lowering RV afterload by reducing pulmonary vascular resistance, prevention of 
thromboembolism, optimization of RV preload, and maintainence of RV inotropy. Initial 
pharmacologic management utilizes pulmonary vasodilators to reduce RV afterload. Several 
pulmonary vasodilators are currently approved for the medical management of PAH; 
however, all therapeutic options for PAH are not advisable for use in patients during 
pregnancy because of the teratogenicity of selected agents. (Figure 1) 
7.2 PAH specific therapy with pulmonary vasodilators  
PAH occurs due to an imbalance of pulmonary vasodilatory and constrictor mediators in the 
pulmonary vasculature causing vasoconstriction, remodeling of the pulmonary vessel wall, 
and thrombosis in situ (Voelkel 1997). Aberrations of many physiologic pathways likely 
contribute to these pulmonary vascular changes and the subsequent development of 
pulmonary hypertension. Three of these pathways are targets for currently approved PAH 
therapies and include the endothelin, prostacyclin, and nitric oxide pathways (Humbert 2004).  
Endothelin is a potent pulmonary vasoconstrictor (Yanisagawa 1988). Endothelin receptor 
antagonists (ERAs) improve outcomes in non-pregnant pulmonary arterial hypertension 
patients (Rubin 2002, Galiè 2008); however, the use of ERAs is not recommended for treatment 
of PAH in pregnancy because of their known teratogenicity (pregnancy risk category X).  
Prostacyclin is a potent pulmonary vasodilator with anti-proliferative (Clapp 2002) and anti-
thrombotic effects (Moncada 1976). The prostacyclin analog, epoprostenol, was the first 
available PAH specific therapy and has been shown to improve functionality, pulmonary 
hemodynamics, and survival in non-pregnant PAH patients (Barst 1996). Epoprostenol is 
the most frequently reported treatment for PAH in pregnancy (Bédard 2009). Epoprostenol 
is classified as a pregnancy risk category B drug and has not been associated with fetal 
abnormalities in recent literature reviews (Stewart 2001, Bédard 2009, Kiely 2010). More 
recently approved prostacyclin analogues include treprostinil and iloprost. Treprostinil 
carries a pregnancy category B risk classification with limited data regarding safety data in 
pregnancy. Iloprost has been shown to be associated with adverse fetal effects in animals 
(pregnancy risk category C) but has been used successfully without adverse human fetal 
effects in a series of 9 patients (Kiely 2010).  
Nitric oxide is a known pulmonary vasodilator (Pepke-Zaba 1991). The nitric oxide pathway 
can be targeted for the treatment of pulmonary hypertension by exogenous delivery of nitric 
oxide or augmentation of nitric oxide dependent cyclic GMP mediated pulmonary 
vasodilatation by inhibiting the breakdown of cyclic GMP by phosphodiesterase type 5 
(PDEI-5) (Humbert 2004). Phosphodiesterase inhibition with sildenafil has been used to treat 
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PAH in pregnancy with no reported complications (Goland 2010, Kiely 2010). The currently 
approved PDEI-5s for the treatment of PAH are pregnancy risk category B. 
Over the last two decades, multiple clinical series and case reports have described 
outcomes and management of PAH in pregnancy. A systematic review of the published 
literature from 1997 to 2007 found 47 case reports with a total of 73 parturients affected by 
PAH (Bédard 2009). Advanced PAH therapies were utilized in 72% of the reported 
patients. Prostacyclin analogues were the most commonly used form of PAH therapy. In 
patients with idiopathic PAH treated with epoprostenol, the mortality rate was 20% 
(Bédard 2009). Overall mortality in PAH patients managed from 1978-96 compared with 
patients managed from 1997-2007 has improved. Mortality has decreased in patients with 
idiopathic PAH (30% to 17%), congenital heart disease associated PAH (36% to 28%) and 
other forms of precapillary PAH (56% to 33%) in the modern era (P = 0.047) (Bédard 2009). 
Prior to the initiation of pharmacologic treatment, detailed discussion of the risks and 
benefits of the various therapeutic options should be undertaken. Based upon the current 
available literature, initiation of a prostacyclin with careful upward titration of the dose as 
tolerated is advisable (Bédard 2009, Kiely 2010, Garabedian 2010). The addition of oral 
sildenafil has been used successfully in the past and could be considered adjunctive therapy 
(Goland 2010, Kiely 2010).  
7.3 Maternal and fetal monitoring  
The optimal monitoring strategy for PAH in pregnancy is unclear at the present time. Initial 
evaluation and commencement of PAH therapy, i.e. prostacyclin, likely will require 
observation in the inpatient setting or prolonged intense monitoring as an outpatient. 
Subsequently, close outpatient monitoring may be considered in the appropriate patient. 
Successful outpatient monitoring has been reported in a series of 9 women with PAH during 
10 pregnancies managed at a quaternary care hospital in the United Kingdom (Kiely 2010). 
These patients were evaluated in the outpatient setting every 4 weeks until week 28 
gestation followed by every 2 weeks until week 30 gestation and then weekly until 24 hours 
prior to scheduled delivery unless clinical worsening occurred that required hospitalization. 
Each outpatient assessment included a history, examination, routine laboratory assessment, 
electrocardiogram, and an exercise tolerance assessment. Maternal cardiac echocardiogram 
was repeated if clinically indicated (Kiely 2010). Once hospitalized, continuous monitoring 
of maternal heart rate and oxygen saturation was performed in all patients. Repeat right 
heart catheterization remains debatable and is not universally utilized during pregnancy for 
evaluation of clinical worsening and/or at the time of delivery (Kiely 2010, Bonnin 2005). 
In a systematic review of outcomes in PAH in pregnancy from 1978-1996 the overall 
neonatal survival ranged from 87% to 89% (Weiss 1998). Fetal monitoring and ultrasound 
biometry (Garabedian 2010, Kiely 2010) often is utilized to monitor fetal growth and 
development. If a fetal abnormality or growth restriction is suspected, further assessment is 
employed to guide management (Kiely 2010). 
7.4 Thromboprophylaxis  
Pregnancy is a hypercoagulable state (Brenner 2004) associated with an increased risk of 
thromboembolic disease. Currently, there is no standard thromboprophylaxis regimen 
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recommended in PAH patients during pregnancy prior to delivery. Anticoagulation risks 
and benefits should be assessed on an individual basis and may not be well tolerated  
in select patient groups such as those with Eisenmenger's Syndrome (Pitts 1977) or other 
bleeding diatheses. Warfarin use is contraindicated in pregnancy due to its known 
teratogenicity (pregnancy risk category X.) Both unfractionated heparin (Bédard 2009)  
and low molecular weight heparin (LMWH) (Kiely 2010, Goland 2010, Garabedian 2010) 
have been successfully used for thromboprophylaxis and treatment in pregnant PAH 
patients. If full dose anticoagulation is chosen, transition to prophylactic dosing should 
occur prior to delivery and may be resumed after delivery if there is no contraindication 
(Kiely 2010).  
7.5 Maintenance of optimal preload and management of anemia 
Volume status should be monitored closely and maintenance of euvolemia should be 
attempted (Piazza 2005). Diuretic therapy may be necessary (Bédard 2009) but should be 
used with caution during the peripartum period when patients are at risk for rapid volume 
shifts and acute hemorrhagic anemia. If acute hemorrhage occurs, addressing the 
underlying cause and resuscitation is paramount to maintain hemodynamic stability 
(Krasuski 2004). If induction of labor is required, oxytocin, prostaglandin F2 should be 
infused slowly and intravenous boluses avoided because they may induce pulmonary 
vasoconstriction (Dagher 1993, Pinder 2002) which would be poorly tolerated. 
7.6 Inotropic support 
The third trimester of pregnancy, labor, and delivery are associated with a marked increase 
in cardiac work (Madden 2009). In women with PAH, the already taxed RV may not be able 
to meet these demands. Management of RV failure in this setting may require urgent 
delivery, dose escalation of pulmonary vasodilators to reduce RV afterload, and possibly 
direct inotropic support (Piazza 2005). 
8. Timing of labor and mode of delivery 
Timing of delivery is usually based upon the maternal and fetal tolerance of pregnancy.  
The risk for maternal deterioration increases as pregnancy progresses and is greatest after 
the majority of pregnancy-induced hemodynamic changes have occurred (approximately 
the 20th to 24th week of gestation) (Cheek 2001). Frequently, delivery is preterm either due 
to maternal worsening or planned delivery at 32-34 weeks gestation (Bédard 2009, Kiely 
2010). 
The optimal mode of labor and delivery remains unclear in patients with PAH and should 
be tailored to fit the individual patient’s needs. A review of 15 consecutive pregnancies in 
women with PAH managed at a referral center in France from 1992 - 2002 revealed an 
overall mortality of 36% and there was not a clear survival advantage associated with any 
particular mode of delivery. Scheduled cesarean section delivery with regional anesthesia 
via epidural or spinal-epidural is reported as the preferred delivery mode in two series. The 
advantages of this approach are daytime scheduling and avoidance of marked 
hemodynamic changes that may occur with vaginal delivery and general anesthesia (Bonnin 
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2005, Kiely 2010). Regional anesthesia with cesarean section has been used successfully in 
several other reported cases (Bédard 2009, Khan 1996, Stewart 2001, Goland 2010). If 
epidural or spinal-epidural anesthesia is chosen, incrementally increasing epidural 
anesthesia is advocated to avoid rapid hemodynamic changes (Smedstad 1994). 
Additionally, the use of bolus spinal anesthesia is not recommended due to the potential for 
hemodynamic compromise. 
Vaginal delivery without epidural anesthesia may not be well tolerated as it is associated 
with dramatic increases in cardiac work due to 12% increases in cardiac output in the first 
stages of labor and 34% in advanced labor at full cervical dilatation (Hunter 1992). If vaginal 
delivery is the chosen mode, epidural anesthesia with low-dose analgesia is recommended 
to reduce the adverse hemodynamic demands of labor (Slomka 1988, Smedstad 1994). 
Furthermore, if oxytocin, prostaglandin F2α, is used to induce labor it should be infused 
slowly to prevent the negative hemodynamic consequences caused by its pulmonary 
vasoconstrictive properties (Slomka 1988). 
General anesthesia has been used successfully in the delivery of patients with PAH 
(Garabedian 2010, Bonnin 2005); however, general anesthesia may be associated with 
pulmonary vasoconstriction and other adverse hemodynamic changes associated with 
mechanical ventilation that may be deleterious in this patient population (Blaise 2003).  
9. Post partum management 
The postpartum period is the most critical time for pregnant PAH patients because the risk 
of morbidity and mortality is greatest due to a marked increase in pulmonary vascular 
resistance and cardiac output (Madden 2009). The majority of these hemodynamic 
alterations resolve in the first 2 weeks after delivery with complete normalization over the 
next 6 months (Cheek 2001). Monitoring post partum patients with PAH in a critical care 
setting is advocated for at least several days (Bonnin 2005) to a week (Kiely 2010) after 
delivery to ensure continued stability. Close monitoring with further escalation of 
pulmonary vasodilators, addition of inotropic support, and packed red blood cell 
transfusions may be required during this vulnerable time. The use of full dose 
anticoagulation is widely utilized in the post partum period and initiated 12-24 hours post 
partum based on the mode of delivery if there is no contraindication (James 2006).  
Once the patient with PAH has been monitored and durable hemodynamic stability 
achieved postpartum, she can be maintained on appropriate PAH therapies (McLaughlin 
2009) and discharged from the hospital with continued management in the outpatient 
setting (Kiely 2010). 
10. Summary 
Despite moderate advances in the management of PAH, pregnancy with concurrent PAH 
remains extremely high risk with significant morbidity and mortality (Bonnin 2005). 
Counseling regarding risks of pregnancy and early termination remain the recommended 
interventions. If a woman with PAH chooses to proceed with pregnancy, a detailed discussion of 
risks should be undertaken. Thorough evaluation and management utilizing a multi-professional 
team (Kiely 2010, Smedstad 1994) and full diagnostic assessment of PAH is recommended.  
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 Thorough evaluation under the care of a multi-
professional team with expertise in 
management of PAH and high risk obstetrics
RHC
 Confirm the diagnosis of PAH
 Assessment of severity
PAH therapy
 Initiate and maintain PAH therapy with goal of 
lowering pulmonary vascular resistance and 
allowing improved tolerance of hemodynamic 
physiologic changes of pregnancy
Monitoring
 Outpatient setting if clinically appropriate
 Inpatient if clinical worsening/hemodynamic 
instability and prior to delivery
Delivery
 Mode of delivery selected based on individual 
patient characteristics
 Possible hemodynamic benefit from planned 
cesarean section with regional anesthesia
Postpartum
 Inpatient monitoring in the critical care setting
 Significant risk for hemodynamic compromise  
in the post-delivery period
 
 
Fig. 1. Right heart catheterization (RHC), Pulmonary arterial hypertension (PAH)  
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PAH therapy should be initiated and gradually increased to maintain hemodynamic 
stability. Inpatient monitoring is recommended in cases of worsening and prior to 
scheduled delivery (Kiely 2010). The optimal mode of delivery is not clear at this time but 
scheduled cesarean section with regional anesthesia has been used successfully in 
multiple case reports (Bédard 2009, Khan 1996, Stewart 2001, Goland 2010). The post 
partum period is the most critical time for worsening and death because of the rapid 
reversal of the physiologic hemodynamic changes of pregnancy. As these alterations 
resolve, post partum patients with PAH should be monitored in a critical care setting for 
several days to a week after delivery and supported medically. After discharge, continued 
close monitoring is recommended as women with PAH are at risk for decompensation for 
several months after delivery. 
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